You're about to put money in. The pitch deck is not evidence.
mar:val checks the target's technology, balance sheet and market position against registers, filed accounts and patent data — and tells you where the evidence runs out.
Cheap or expensive? Depends what you look at.
A single fair value has to be believed. Five that disagree can be judged. Switch the basis — from earnings to revenue the verdict flips from overvalued to undervalued, and book value puts the price a third above fair. That spread is the more honest answer.
A share price across 24 periods, behind it a fair-value line with valuation bands from ten to forty per cent. The line and the over- or undervaluation verdict change with the chosen valuation basis.
What actually helps in a review
Mar:lean Ranking 0–100
One composite score per company, plus five sub-ratings: revenue in the technology sector, CAGR, R&D share, innovation score, portfolio value.
Insolvency risk, twice over
Altman Z′ — the private-company variant, with its safe, grey and distress zones — and Zmijewski as a probability. Unlisted targets included, with the inputs researched where no filing exists.
Fair value on five bases
Earnings, revenue, book value, EBIT and dividend against the actual price, with valuation bands and the methodology shown.
Capital flows with a source
Funding rounds in, acquisitions and stakes out — with date, amount, investors and a linked reference.
Innovation matrix
Revenue growth against patent growth. Does the filing activity carry the growth story, or tell a different one?
Ownership down to a person
Hop by hop through the official register up to natural persons, with beneficial owners and group structure.
Patents judged one by one
Per family: core, blocking, improvement, defensive or legacy, with a strength score and its risk. The portfolio as a whole read as moat, bargaining chip, defensive cover or peripheral.
Freedom-to-operate screening
Who can block you, claim by claim against product features, with design-around options. Screening, not a legal opinion — have counsel review what you act on.
Comparison against a baseline
Several targets side by side, columns sortable, deviations from the reference company colour-marked.
Where the evidence runs out, it says so
Due diligence rarely fails for want of numbers. It fails on numbers whose origin nobody knows. mar:val keeps the two apart: anything counted comes out of the database, and judgements are marked as judgements.
See the data behind mar:val- No counted figure originates in the model — numbers come from the database.
- Every technical assertion points to a publication number, a dated event or a named source.
- Missing evidence never yields "low risk", it yields "not rated".
- A complete screen against a partial one, with the gaps listed explicitly.
- Shareholdings appear in the bands the register publishes — 75 to 100 per cent stays 75 to 100 per cent.
What you are probably asking now
Each company shows which source a value came from and whether it was fetched fresh or served from cache. Legal statuses carry an as-of date and are flagged for re-verification after six months.
The other five situations
Know what your technology is worth.
In the demo we show you a real report from your technology field. 30 minutes, no obligation.
Questions first? kontakt@marlean.com